The dynamics of antimicrobial resistance in bacteria are informed by the fitness advantages conferred by genetic determinants of resistance in the presence of antibiotic pressure and the potential fitness costs in its absence. However, frameworks for quantitative estimates of real-world fitness impact have been lacking, given multidrug resistance, multiple pathways to resistance, and uncertainty around drug exposures. Here, we addressed these challenges through analysis of genome sequences from clinical isolates of